- News & Updates
Aripiprazole (Abilify, Abilify Maintena, Aristada) – Further FDA Warnings About New Impulse-Control Problems
On May 3, 2016 the U.S. Food and Drug Administration (FDA) added warnings about compulsive behaviors associated with aripiprazole products including Abilify, Abilify Maintena, Aristada.
Pathological gambling is already listed as a reported effect. The current warning, however, doesn’t comprehensively cover the impulse-control risk identified by the FDA. FDA reported other compulsive behaviors such as compulsive eating, shopping and sexual actions are associated with aripiprazole.
Read Related Articles: